Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 3,785.9	$ 3,909.5	$ 7,439.4	$ 7,628.6
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,363.1	2,444.7	4,672.2	4,865.0
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,422.8	1,464.8	2,767.2	2,763.6
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	348.4	380.0	737.3	797.9
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	161.9	182.4	338.2	385.1
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	124.3	137.1	238.5	281.4
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	106.1	111.0	206.8	226.0
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	115.5	127.5	195.7	223.3
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	72.2	82.0	144.4	170.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	62.7	64.8	122.1	129.4
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	58.9	54.5	116.9	111.0
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	78.2	74.1	153.2	146.8
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	45.6	50.4	88.1	97.1
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	36.9	41.5	69.9	78.1
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	35.4	51.8	69.9	91.5
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	55.0	57.7	103.2	110.9
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	54.5	55.0	109.7	102.0
Developed Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,233.8	1,300.2	2,412.6	2,532.2
Developed Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	1,085.4	1,053.6	2,072.0	1,992.0
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	535.7	530.5	1,077.5	1,092.9
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	3.3	1.6	5.4	3.8
Japan, Australia and New Zealand Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	198.4	207.4	382.5	397.7
Japan, Australia and New Zealand Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	151.2	168.1	284.9	320.0
Emerging Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	395.2	406.6	799.6	842.2
Emerging Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	182.9	241.5	404.9	447.8
Operating Segment | Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	2,319.2	2,353.8	4,484.6	4,524.2
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	539.0	532.1	1,082.9	1,096.7
Operating Segment | Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	349.6	375.5	667.4	717.7
Operating Segment | Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 578.1	$ 648.1	$ 1,204.5	$ 1,290.0